A prospective, single-center, randomized phase 2 trial of etoposide in severe COVID-19
Halpin, M.; Lerner, A.; Sagar, M.; Govender, P.; Shah, B.; Weinberg, J.; Sarosiek, S.; Sloan, J. M.
Show abstract
The systemic inflammatory response seen in patients with severe COVID-19 shares many similarities with the changes observed in hemophagocytic lymphohistiocytosis (HLH); a disease characterized by excessive immune activation. Many patients with severe COVID qualify for a diagnosis of HLH. Etoposide, an inhibitor of topoisomerase II is used to control inflammation in HLH. This randomized, open-label, single center phase II trial attempted to determine whether etoposide can be used to blunt the inflammatory response in severe COVID. This trial was closed early after eight patients were randomized. This underpowered trial did not meet its primary endpoint of improvement in pulmonary status by two categories on an 8 point ordinal scale of respiratory function. There were not significant differences in secondary outcomes including overall survival at 30 days, cumulative incidence of grade 2 through 4 adverse events during hospitalization, duration of hospitalization, duration of ventilation and improvement in oxygenation or paO2/FIO2 ratio or improvement in inflammatory markers associated with cytokine storm. A high rate of grade 3 myelosuppression was noted in this critically ill population despite dose reduction, a toxicity which will limit future attempts to explore the utility of etoposide for virally-driven cytokine storm or HLH.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa Trial 93%
- Opaganib in COVID-19 pneumonia: Results of a randomized, placebo-controlled Phase 2a trial 93%
- Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial 92%
Similar papers in this journal
- Hydroxychloroquine For The Treatment Of Severe Respiratory Infection By COVID-19: A Randomized Controlled Trial 94%
- Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19 93%
- Safety and effectiveness of RBD-specific polyclonal equine F(ab′)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: a retrospective cohort study 93%
Similar papers in this journal
- Compassionate Use of REGEN-COV ® in Patients with COVID-19 and Immunodeficiency-Associated Antibody Disorders 95%
- A Multi-center, Prospective, Observational-cohort controlled study of Clinical Outcomes following COVID-19 Convalescent plasma therapy in hospitalized COVID-19 patients 94%
- SARS-CoV-2 RNAaemia predicts clinical deterioration and extrapulmonary complications from COVID-19 92%
Similar papers in this journal
- Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients 92%
- Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19 92%
- A unique dexamethasone-dependent gene expression profile in the lungs of COVID-19 patients 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.